Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5754930 | 0.98 | DPP7 (0.96) | DPP7SIGMAR1SLC6A3KMT2AMEN1 | |
| SCHEMBL8883456 | 0.98 | DPP7 (0.96) | DPP7SIGMAR1SLC6A3KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5758454 | 0.96 | DPP7 (0.93) | DPP7SIGMAR1SLC6A3KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5759171 | 0.96 | DPP7 (0.93) | DPP7SIGMAR1SLC6A3KMT2AMEN1 | |
| SCHEMBL3165932 | 0.90 | DPP7 (0.82) | DPP7SIGMAR1KMT2AAPPCYP3A4 | |
| SCHEMBL3171554 | 0.89 | DPP7 (0.79) | DPP7SIGMAR1KMT2AAPPCYP3A4 | |
| Hydrochloric Acid SCHEMBL10606789 | 0.86 | DPP7 (0.76) | DPP7SIGMAR1SLC6A3MAOACYP3A4 | |
| SCHEMBL39631 | 0.84 | DPP7 (0.73) | DPP7SIGMAR1KMT2AMEN1TDP1 | |
| SCHEMBL9048454 | 0.84 | DPP7 (0.73) | DPP7SIGMAR1KMT2AMEN1TDP1 | |
| SCHEMBL9019137 | 0.84 | SIGMAR1 (1.00) | DPP7SIGMAR1SLC6A3DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691136-B2 | Olefin oligomerization catalyst and method for producing olefin oligomer in the presence of the same catalyst | MITSUI CHEMICALS, INC. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-11691136-B2 | Olefin oligomerization catalyst and method for producing olefin oligomer in the presence of the same catalyst | MITSUI CHEMICALS, INC. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20200222886-A1 | OLEFIN OLIGOMERIZATION CATALYST AND METHOD FOR PRODUCING OLEFIN OLIGOMER IN THE PRESENCE OF THE SAME CATALYST | MITSUI CHEMICALS, INC. (JP) | 2020-07-16 | — | — | US | disclosed |
| US-9920010-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-20 | — | — | US | disclosed |
| EP-3004082-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-3004082-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191929-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-04 | — | — | WO | disclosed |
| EP-1401821-A4 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORP (KR) | 2006-05-31 | — | — | EP | disclosed |
| EP-1401821-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK Corporation (KR) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002100848-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORPORATION (KR) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | DPP7 1861/4885SIGMAR1 166/4885SLC6A3 1418/4885 |
| US-20200222886-A1 | OLEFIN OLIGOMERIZATION CATALYST AND METHOD FOR PRODUCING OLEFIN OLIGOMER IN THE PRESENCE OF THE SAME CATALYST | OXER1, COG6, CBR1 | DPP7 4684/4885SIGMAR1 505/4885SLC6A3 4426/4885 |
| US-11691136-B2 | Olefin oligomerization catalyst and method for producing olefin oligomer in the presence of the same catalyst | OXER1, COG6, CBR1 | DPP7 4684/4885SIGMAR1 505/4885SLC6A3 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.